BASF subsidiary Metanomics Health launches MetaMap®Tox|
Monday, August 13, 2012
MetaMap®Tox is a service evaluating specific metabolomic patterns in vivo, enabling customers to better and faster identify potential safety risks of test compounds in in vivo studies of rats.
Developed in-house by BASF’s Experimental Toxicology and Ecology unit and marketed through Metanomics Health, MetaMap®Tox addresses key unmet needs for in vivo toxicology testing: predictability, understanding of a toxicology mechanism and the ability for translation to clinical use.
Zetasizer Nano Delivers Essential Data in Environmental Nanosafety Work in Canada
Tuesday, August 07, 2012
Researchers at the University of Alberta, Canada are working as part of a major Canadian initiative to investigate the aquatic and environmental aspects of nanoparticles.
xCELLigence System Evaluated in EU Project to Replace Animal Experiments in Cosmetics Industry
Monday, April 02, 2012
Roche’s xCELLigence RTCA System is being used in the European Union’s SEURAT initiative to run five years from 2011 to 2016.
Thermo Fisher Scientific Introduces New Screening Tool for Developmental Neurotoxicity
Monday, March 19, 2012
Offers consumer and health products Industries a high-throughput, animal-free approach to identify developmental neurotoxins.
CellMade Targets Inflammatory Biology Products and Services
Monday, March 19, 2012
Company introduces their new site, featuring free poster and protocol downloads as well as updated information on the CellInsight™ platform and REACT-lipid™ service.
Molecular Devices Introduces ScreenWorks® Peak Pro™ Software
Wednesday, February 29, 2012
Analysis model offers the ability to analyze multi-peak calcium oscillation responses of cells, and in particular beating cardiomyocytes, to characterize cardiotoxic and cardioactive compounds during a high throughput screen.
Simcyp Develops Virtual Laboratory Mouse for Use in Cancer and Toxicology Research
Friday, January 20, 2012
The Simcyp Mouse provides a virtual environment for evaluating drug disposition which will replace the need for some live animal testing in normal as well as transgenic mice, thus reducing and refining preclinical investigation.
Cyprotex Introduces Genomic ADME Service
Friday, December 09, 2011
Cyprotex plc now provides the service, which can provide researchers with actionable data about genomic differences in drug response at the early stages of drug development.
New Sorbent is Designed and Tested for Drugs of Abuse Extraction in Forensic Toxicology
Wednesday, January 19, 2011
Phenomenex Inc. have introduced Strata™-X-Drug B, a new solid phase extraction (SPE) sorbent specially designed and quality-control tested for drugs of abuse. Strata-X-Drug B, a polymeric strong cation-exchange SPE sorbent, does not require conditioning, saving time and solvent expense.
|<< || 1 2 3 4 5 ||>>|
|Showing Results 41 - 49 of 49||